Skip to content

Price / book at other companies

Boston Scientific logo
Boston ScientificBSX
3.6×-3.1×
AngioDynamics logo
AngioDynamicsANGO
2.7×+0.7×
InfuSystem Holdings logo
InfuSystem HoldingsINFU
3.2×+1.1×
Delcath Systems logo
Delcath SystemsDCTH
2.9×-2.4×
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
2.7×+1.2×
LQD
Liquidia CorporationLQDA
30.6×+5.3×

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%
Debt / equity2.6×
Current ratio5.8×+3.6×

Where this comes from

Calculated from TriSalus Life Sciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s price / book?
TriSalus Life Sciences, Inc. (TLSI) reported price / book of 19.1× in Q1 2026.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.